A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
Gleason score
active surveillance
prostate cancer
survey
urologic oncology
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
19
05
2022
accepted:
13
11
2022
pubmed:
24
11
2022
medline:
8
3
2023
entrez:
23
11
2022
Statut:
ppublish
Résumé
To conduct a national questionnaire survey of Japanese urologists on active surveillance (AS) for low- and intermediate-risk prostate cancer (PCa). A questionnaire was sent to 922 Japanese Urological Association Teaching Base Hospitals. The items included were years of experience as a urologist, sex, workplace, treatment equipment owned, specialty area of daily practice, specialty area of urological cancer, and six hypothetical cases of AS. The cases were categorized by the following Gleason scores: 3 + 3 low risk of PCa, 3 + 4 intermediate risk, and 4 + 3 intermediate risk, with or without comorbidities for each case. Comorbidities were defined as cardiovascular diseases or illnesses warranting anticoagulant therapy. Altogether, 1962 questionnaires were analyzed. Responses were almost equally distributed among all age groups. Workplaces included general hospitals (49.4%), university hospitals (40.3%), and cancer centers (4.2%). Percentages of proposed AS for low risk/no comorbidity, low risk/with comorbidity, intermediate-risk 3 + 4/no comorbidity, intermediate risk 3 + 4/with comorbidity, intermediate risk 4 + 3/no comorbidity, and intermediate risk 4 + 3/with comorbidity were 90.5%, 90%, 39.5%, 48.7%, 15%, and 22%, respectively. Analysis of the correspondents' backgrounds showed that the more the urologists' years of experience, the less they were to advise AS of low-risk patients. In the presence of comorbidities, urologists across all age groups tended to propose AS, even in the same Gleason grade group. Cancer center urologists recommended AS more often than their counterparts at general and university hospitals. Approximately 40% of urologists proposed AS for intermediate-risk cases, confirming that AS for intermediate-risk patients is being considered in Japan.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-297Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Japanese Urological Association.
Références
Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272-7.
Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol. 2015;33:3379-85.
Carlsson S, Benfante N, Alvim R, Sjoberg DD, Vickers A, Reuter VE, et al. Risk of metastasis in men with grade group 2 prostate cancer managed with active surveillance at a tertiary cancer center. J Urol. 2020;203:1117-21.
Thostrup M, Thomsen FB, Iversen P, Brasso K. Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scand J Urol. 2018;52:14-9.
Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, et al. Effects of initial Gleason grade on outcomes during active surveillance for prostate cancer. Eur Urol Oncol. 2018;1:386-94.
Savdie R, Aning J, So AI, Black PC, Gleave ME, Goldenberg SL. Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urol Oncol. 2017;35:605.e1-8.
Nyame YA, Almassi N, Haywood SC, Greene DJ, Ganesan V, Dai C, et al. Intermediate-term outcomes for men with very low/low and intermediate/high risk prostate cancer managed by active surveillance. J Urol. 2017;198:591-9.
Musunuru HB, Yamamoto T, Klotz L, Ghanem G, Mamedov A, Sethukavalan P, et al. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol. 2016;196:1651-8.
Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J. Long-term results of active surveillance in the Goteborg randomized, population-based prostate cancer screening trial. Eur Urol. 2016;70:760-6.
Bul M, van den Bergh RC, Zhu X, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672-7.
Network NCC. NCCN clinical practice guidelines in oncology: prostate cancer, version 3.2022. PA 19462 United States: National Comprehensive Cancer Network; 2022.
Kim SP, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, et al. Recommendations of active surveillance for intermediate-risk prostate cancer: results from a National Survey of radiation oncologists and urologists. Eur Urol Oncol. 2019;2:189-95.
McClelland S 3rd, Sandler KA, Degnin C, Chen Y, Mitin T. Active surveillance for low and intermediate risk prostate cancer: opinions of north American genitourinary oncology expert radiation oncologists. Clin Genitourin Cancer. 2018;16:e323-5.
Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25:524-31.
Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430-9.
Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent patterns of multimorbidity among older adults in high-income countries. Popul Health Manag. 2019;22:127-37.
Mitsutake S, Ishizaki T, Teramoto C, Shimizu S, Ito H. Patterns of Co-occurrence of chronic disease among older adults in Tokyo, Japan. Prev Chronic Dis. 2019;16:E11.
Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, et al. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014;44:969-81.
Nakai Y, Tanaka N, Fujii T, Miyake M, Anai S, Hori S, et al. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: an analysis of 10 839 patients from the Nara urological research and treatment group registry between 2004 and 2015. Int J Urol. 2021;28:1164-70.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428-35.
Kim SP, Tilburt JC, Shah ND, Yu JB, Konety B, Nguyen PL, et al. A National Survey of radiation oncologists and urologists on perceived attitudes and recommendations of active surveillance for low-risk prostate cancer. Clin Genitourin Cancer. 2019;17:e472-81.